Rapid discovery and optimization of therapeutic antibodies against emerging infectious diseases

Protein Engineering, Design and Selection

Volumn 21, Issue 8, 2008, Pages 495-505

  Rogers, J ^a   Schoepp, R J ^b   Schroder O ^a   Clements, T L ^b   Holland, T F ^a   Li, J Q ^a   Li, J ^a   Lewis, L M ^a   Dirmeier, R P ^a   Frey, G J ^a   Tan, X ^a   Wong, K ^a   Woodnutt, G ^a   Keller, M ^a   Reed, D S ^b   Kimmel, B E ^a   Tozer, E C ^a  

^a DIVERSA CORPORATION   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

Antibody discovery; Humanized; Optimized; SARS CoV

Indexed keywords

ANIMAL MODELS; CAUSATIVE AGENTS; EVOLUTION STRATEGIES (ESS); IN-VITRO; INFECTIOUS DISEASES; NEUTRALIZING ANTIBODIES; OPTIMIZATION TOOLS; REASSEMBLY; SARS CORONAVIRUS; SATURATION MUTAGENESIS; SINGLE POINT MUTATIONS;

HEALTH; NUCLEIC ACIDS; OPTIMIZATION; ORGANIC ACIDS;

ANIMAL CELL CULTURE;

ANTIBODY; CHIMERIC ANTIBODY; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIVISION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VIRUS ATTACHMENT; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; CERCOPITHECUS AETHIOPS; COMMUNICABLE DISEASES, EMERGING; DIRECTED MOLECULAR EVOLUTION; DRUG DISCOVERY; HUMANS; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; POINT MUTATION; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VERO CELLS;

ANIMALIA; SARS CORONAVIRUS;

EID: 47649119828     PISSN: 17410126     EISSN: 17410134     Source Type: Journal    
DOI: 10.1093/protein/gzn027     Document Type: Article

References (27)

1. Barrios, Y., Knor,S., Lantto,J., Mach,M. and Ohlin,M. (2007) Mol. Immunol., 44, 680-690.
2. Burton,D.R. (2002) Nat. Rev., 2, 706-713.
3. Casadevall,A. (2002) Nat. Biotech., 20, 114.
4. Clark,M. (2000) Immunol. Today, 21, 397-402.
5. Coughlin,M., Lou,G., Martinex,O., Masterman,S.K., Olsen,O.A., Moksa,A.A., Farzan,M., Babcook,J.S. and Prabhakar,B.S. (2007) Virology, 361, 93-102.
6. Dall'Acqua,W.F., Damschroder,M.M., Zhang,J., Woods,R.M., Widjaja,L., Yu,J. and Wu,H. (2005) Methods, 36, 43-60.
7. Davies,J. and Riechmann,L. (1994) FEBS Lett., 339, 285-290.
8. Essono,S., Frobert,Y., Grassi,J., Creminon,C. and Boquet,D. (2003) J. Immunol. Methods, 279, 251-266.
9. Gray,K.A., Richardson,T.H., Kretz,K., Short,J.M., Bartnek,F., Knowles,R., Kan,L., Swanson,P.E. and Robertson,D.E. (2001) Adv. Synth. Catal, 343, 607-617.
10. Greenough,T.C. et al. (2005) J. Infect. Dis., 191, 507-514.
11. Hartings,J.M. and Roy,C.J. (2004) J Pharmacol Toxicol Methods, 49, 39-55.
12. Hudson,P.J. and Souriau,C. (2003) Nature Med., 9, 129-134.
13. Hwang,W.Y.K., Almagro,J.C., Buss,T.N., Tan,P. and Foote,J. (2005) Methods, 36, 35-42.
14. Juckett,G. (2006) Am. Fam. Physician, 74, 783-790.
15. Kretz,K.A., Richardson,T.H., Gray,K.A., Robertson,D.E., Tan,X. and Short,J.M. (2004) Methods Enzymol., 388, 3-14.
16. Lantto,J., Fletcher,J.M. and Ohlin,M. (2003) Virology, 305, 201-209.
17. Li,M. (2000) Nature Biotech., 18, 1251-1256.
18. Meissner,H.C. and Long,S.S. (2003) Pediatrics, 112, 1447-1452.
19. Nelson,J.D. et al. (2007) J. Virol., 81, 4033-4043.
20. Ohlin,M., Ownman,H., Mach,M. and Borrebaeck,C.A.K. (1996) Mol. Immunol., 33, 47-56.
21. Palackal,N. et al. (2004) Protein Sci., 13, 494-503.
22. Roberts,A., Paddock,C., Vogel,L., Butler,E., Zaki,S. and Subbarao,K. (2005) J. Virol., 79, 5833-5838.
23. Schroff,R.W., Foon,K.A., Beatty,S.M., Oldham,R.K. and Morgan,A.C. Jr (1985) Cancer Res., 45, 879-885.
24. Sui,J., Li,W., Roberts,A., Matthews,L.J., Murakami,A., Vogel,L., Wong,S.K., Subbarao,K., Farzan,M. and Marasco,W.A. (2005) J. Virol., 79, 5900-5906.
25. Tellier,R. (2006) Emerg. Infect. Dis., 12, 1657-1662.
26. Thomas,J.K. and Noppenberger,J. (2007) Am. J. Health Syst. Pharm., 64, 149-165.
27. World Health Organization WHO (2003) Summary of Probable SARS Cases with Onset of Illness from 1 November 2002 to 31 July 2003, revised September 26, 2003. www.who.int/csr/sars/country/table2003_09_23/en/